Axogen Corporation
BiotechAxogen Corporation is a biotechnology company focused on Oncology.
Axogen Corporation's Key Drugs
Axogen Corporation's core commercial portfolio centers on avance nerve graft, spanning Oncology — its most strategically important drugs approved in the last 15 years.
Axogen Corporation's Recent FDA Approvals
Axogen Corporation secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Axogen Corporation's Therapeutic Areas
Axogen Corporation's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Axogen Corporation's Top Competitors
Axogen Corporation's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Axogen Corporation Pipeline Snapshot
Axogen Corporation has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • avance nerve graft leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-12-02
- Latest
- 2025-12-02
- Applications
- 1